

Hello,

This letter is to inform you of changes to the Wegovy® licence for the following **Wegovy® FlexTouch® pens: 0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg and 2.4 mg.**

Until now, Wegovy® has been subject to full 'cold chain' requirements during transit – meaning the medicine had to be kept cold from where it is made to where it is used. This means you will have received your Wegovy® in a cooled package.

Due to recent updates to the Wegovy® licence it has been confirmed that these pens can be transported to you, the patient, at temperatures below 30°C for up to 48 hours. Because of this, your prescriber or pharmacy may use a different delivery method than before, and your Wegovy® may not arrive in a cooled package.

**This change does not change how Wegovy® is intended to be used, please refer to the patient information leaflet.**

If you have any questions about your delivery, your pharmacy or prescriber will be able to help.

Yours faithfully,

Novo Nordisk - the manufacturers of Wegovy®

▼ This medicine is subject to additional monitoring. This will allow quick identification of new safety information promptly. You can help by reporting any side effects you may get.  
See [https:// yellowcard.mhra.gov.uk/](https://yellowcard.mhra.gov.uk/) for how to report side effects.

If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. Side effects should also be reported to Novo Nordisk Limited (Telephone Novo Nordisk Customer Care Centre 0800 023 2573).

Calls may be monitored for training purposes.

By reporting side effects, you can help provide more information on the safety of this medicine.